Chimeric antigen receptor T cells (also known as CAR T cells) are T cells that have been genetically engineered to produce an artificial T-cell receptor. Chimeric antigen receptors (CARs, also known as chimeric immunoreceptors, chimeric T cell receptors or artificial T cell receptors) are receptor proteins that have been engineered to give T cells the new ability to target a specific protein. The receptors are chimeric because they combine both antigen-binding and T-cell activating functions into a single receptor. CAR-T cell therapy uses T cells engineered with CARs for cancer therapy. The premise of CAR-T immunotherapy is to modify T cells to recognize cancer cells in order to more effectively target and destroy them. Scientists harvest T cells from people, genetically alter them, then infuse the resulting CAR-T cells into patients to attack their tumors. CAR-T cells can be either derived from T cells in a patient's own blood (autologous) or derived from the T cells of another healthy donor (allogenic). Once isolated from a person, these T cells are genetically engineered to express a specific CAR, which programs them to target an antigen that is present on the surface of tumors. For safety, CAR-T cells are engineered to be specific to an antigen expressed on a tumor that is not expressed on healthy cells.
This report contains market size and forecasts of CAR T-Cell Therapy in Global, including the following market information:
Global CAR T-Cell Therapy Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global CAR T-Cell Therapy market was valued at 472.9 million in 2021 and is projected to reach US$ 3449.4 million by 2028, at a CAGR of 32.8% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Allogeneic Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of CAR T-Cell Therapy include Celgene (Juno Therapeutics), Novartis, Gilead (Kite Pharma), Pfizer, CARsgen Therapeutics, Autolus Therapeutics, Aurora BioPharma, Sorrento Therapeutics and Mustang Bio, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the CAR T-Cell Therapy companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global CAR T-Cell Therapy Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global CAR T-Cell Therapy Market Segment Percentages, by Type, 2021 (%)
Allogeneic
Autologous
Global CAR T-Cell Therapy Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global CAR T-Cell Therapy Market Segment Percentages, by Application, 2021 (%)
Hospitals
Cancer Research Centers
Others
Global CAR T-Cell Therapy Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global CAR T-Cell Therapy Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies CAR T-Cell Therapy revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies CAR T-Cell Therapy revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Celgene (Juno Therapeutics)
Novartis
Gilead (Kite Pharma)
Pfizer
CARsgen Therapeutics
Autolus Therapeutics
Aurora BioPharma
Sorrento Therapeutics
Mustang Bio
Bluebird Bio
Collectis
Allogene Therapeutics
Celyad